Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Arch Biopartners Inc: Arch Biopartners begins recruiting patients for Pontiak | 3 | Stockwatch | ||
Di | Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI) | 67 | GlobeNewswire (Europe) | TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled "Prevention... ► Artikel lesen | |
22.04. | Arch Biopartners Inc: Arch partner TGH receives approval for phase II trial | 1 | Stockwatch | ||
22.04. | Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) | 1 | GlobeNewswire (USA) | ||
11.04. | Arch Biopartners Inc: Arch Biopartners 235,000-share private placement | 2 | Stockwatch | ||
ARCH BIOPARTNERS Aktie jetzt für 0€ handeln | |||||
14.03. | Arch Biopartners Inc: Arch Biopartners closes $374,000 private placement | 1 | Stockwatch | ||
14.03. | Arch Biopartners Closes Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
05.03. | Arch Biopartners Inc: Arch Biopartners arranges $350,000 private placement | 1 | Stockwatch | ||
05.03. | Arch Biopartners Arranges Non-Brokered Private Placement | 1 | GlobeNewswire (USA) | ||
26.02. | Arch Biopartners Inc: Arch Biopartners 31,112 shares for debt | 1 | Stockwatch | ||
18.02. | Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI) | 111 | GlobeNewswire (Europe) | TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the clinical team leading the upcoming investigator-led... ► Artikel lesen | |
04.02. | Arch Biopartners Inc: Arch Biopartners arranges $57,246 shares for debt deal | 1 | Stockwatch | ||
03.02. | Arch Biopartners: Shares for Interest Debt Settlement | 1 | GlobeNewswire (USA) | ||
08.01. | Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI) | 127 | GlobeNewswire (Europe) | TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics... ► Artikel lesen | |
11.11.24 | Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury | 150 | GlobeNewswire (Europe) | TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in... ► Artikel lesen | |
02.08.24 | Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins | 149 | GlobeNewswire (Europe) | Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,560 | +1,24 % | QIAGEN N.V.: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels | Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications... ► Artikel lesen | |
EVOTEC | 6,230 | +0,48 % | Evotec-Aktie mit Kursgewinnen (7,326 €) | Am deutschen Aktienmarkt liegt die Aktie von Evotec aktuell im Plus. Der jüngste Kurs betrug 7,33 Euro. Für das Wertpapier von Evotec steht gegenwärtig ein Wertanstieg 0,33 Prozent zu Buche. Die Aktie... ► Artikel lesen | |
VERVE THERAPEUTICS | 11,080 | 0,00 % | Aktien New York Schluss: Verluste - Sorgen um Krieg in Nahost nehmen zu | NEW YORK (dpa-AFX) - Die sich zuspitzende Lage in Nahost und die Unsicherheit über das weitere Vorgehen der USA haben am Dienstag die US-Börsen belastet. Der New Yorker Leitindex Dow Jones Industrial... ► Artikel lesen | |
CG ONCOLOGY | 26,010 | 0,00 % | Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock | ||
RECURSION PHARMACEUTICALS | 6,540 | 0,00 % | Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings | ||
ARCUTIS BIOTHERAPEUTICS | 14,550 | +1,46 % | Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth | ||
IMMUNOME | 11,070 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
BIONTECH | 94,90 | +0,21 % | BioNTech: Ryan Richardson verlässt Vorstand im Herbst | Bei BioNTech steht ein Wechsel im Vorstand bevor. Ryan Richardson wird seine Position als Chief Strategy Officer sowie seine Ämter in Tochtergesellschaften der BioNTech-Gruppe zum 30. September 2025... ► Artikel lesen | |
PRIME MEDICINE | 4,530 | 0,00 % | JMP bestätigt Kursziel von 6 US-Dollar für Prime Medicine nach Finanzierung durch Mukoviszidose-Stiftung | ||
RELAY THERAPEUTICS | 3,710 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
POLYRIZON | 1,420 | 0,00 % | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | Ra'anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
LENZ THERAPEUTICS | 32,980 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
COGENT BIOSCIENCES | 12,445 | 0,00 % | Cogent Biosciences auf Rekordhoch: Positive Studienergebnisse und Kapitalerhöhung beflügeln Kurs | ||
CRISPR THERAPEUTICS | 56,00 | -0,88 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
BEAM THERAPEUTICS | 21,540 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen |